Adjuvant therapy for melanoma: a surgical perspective.
Adjuvant therapy is commonly used in melanoma because recurrence after surgery usually results in the patient's eventual death. Surgeons have a profound influence on patients' decisions regarding adjuvant therapy, beginning with providing a clear understanding of the risk of specific types of recurrence. This review summarizes the potential oncologic benefits and relevant toxicities of adjuvant systemic therapies for melanoma that are currently available and under investigation.
Department of Cutaneous Oncology, H. Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Drive, Tampa, FL 33612, USA. vernon.sondak@moffitt.org
Vernon K
VK
Sondak
Ricardo J
RJ
Gonzalez
Ragini
R
Kudchadkar
D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D000998:Antiviral Agents / Q000008:administration & dosage / Q000627:therapeutic use; D019496:Cancer Vaccines; D016178:Granulocyte-Macrophage Colony-Stimulating Factor; D006801:Humans; D007167:Immunotherapy; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage / Q000627:therapeutic use; D000074324:Ipilimumab; D008198:Lymph Nodes; D008545:Melanoma / Q000188:drug therapy / Q000276:immunology* / Q000473:pathology; D009364:Neoplasm Recurrence, Local; D011092:Polyethylene Glycols / Q000008:administration & dosage / Q000627:therapeutic use; D011994:Recombinant Proteins; D018570:Risk Assessment; D012878:Skin Neoplasms / Q000188:drug therapy / Q000276:immunology* / Q000473:pathology
D000911:Antibodies, Monoclonal; D000998:Antiviral Agents; D019496:Cancer Vaccines; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D000074324:Ipilimumab; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D016178:Granulocyte-Macrophage Colony-Stimulating Factor; C100416:peginterferon alfa-2a